EUVIMEDEUVIMED entdecken
Crossref

Prospective Randomized Open Label Comparative Study of Efficacy of Atorvastatin Alone and Atorvastatin with Omega 3 Fatty Acids in Patients with Dyslipidaemia Attending Tertiary Care Hospital

Neha Fatima, Ajit Kishor, Rani Indira Sinha, Keshav Kumar Sinha, Md Ejaz Alam

International Journal of Current Pharmaceutical Review and Research · 30.04.2026 · 18 (04)

DOI: 10.25258/ijcpr.18.4.201 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Current Pharmaceutical Review and Research, online erschienen am 30.04.2026. Verfasst von Neha Fatima und 4 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Dyslipidaemia is an important modifiable cardiovascular risk factor which is highly prevalent in the Indian population. Atorvastatin reduces low-density lipoprotein cholesterol (LDL-C), but a large proportion of patients have elevated triglycerides and residual cardiovascular risk. Omega-3 fatty acids have been demonstrated to lower triglycerides, and may offer added benefit when used in combination with statins.

Methods

This prospective, open-label, randomized comparative study was carried out between February 2020 to August 2021 at a tertiary care hospital- Aryabhatta. One hundred dyslipidaemia patients were assigned to either Group A (atorvastatin 10–20 mg once daily) or Group B (atorvastatin 10–20 mg + omega-3 fatty acids 1 g twice daily) with a random allocation. Treatment duration was 12 weeks. Lipid profiles were evaluated at baseline, 6 weeks and 12 weeks. Statistical analysis was conducted with SPSS, and p < 0.05 was considered statistically significant.

Results

There was a statistically significant improvement among the study and control groups in the 12 weeks for all lipid parameters (p < 0.001). The combination therapy group also showed much decreased triglycerides and slightly increased high-density lipoprotein cholesterol (HDL-C) as compared to atorvastatin monotherapy. Both groups had a significant reduction in LDL-C, which was slightly greater in the combination group. Tolerability of both regimens was good with minimal adverse effects.

Conclusion

Atorvastatin plus omega-3 fatty acids was more effective than atorvastatin alone, especially in the reduction of triglycerides and similarly safe. Combination therapy can help in the management of patients with mixed dyslipidaemia; however, large multicentric trials are required to determine long-term cardiovascular outcomes.

Zitieren

APA

Fatima, N., Kishor, A., Sinha, R. I., Sinha, K. K., & Alam, M. E. (2026). Prospective Randomized Open Label Comparative Study of Efficacy of Atorvastatin Alone and Atorvastatin with Omega 3 Fatty Acids in Patients with Dyslipidaemia Attending Tertiary Care Hospital. International Journal of Current Pharmaceutical Review and Research, 18(04). https://doi.org/10.25258/ijcpr.18.4.201

Vancouver

Fatima N, Kishor A, Sinha RI, Sinha KK, Alam ME. Prospective Randomized Open Label Comparative Study of Efficacy of Atorvastatin Alone and Atorvastatin with Omega 3 Fatty Acids in Patients with Dyslipidaemia Attending Tertiary Care Hospital. International Journal of Current Pharmaceutical Review and Research. 2026;18(04). doi:10.25258/ijcpr.18.4.201

BibTeX
@article{Fatima2026,
  author = {Fatima, Neha and Kishor, Ajit and Sinha, Rani Indira and Sinha, Keshav Kumar and Alam, Md Ejaz},
  title = {Prospective Randomized Open Label Comparative Study of Efficacy of Atorvastatin Alone and Atorvastatin with Omega 3 Fatty Acids in Patients with Dyslipidaemia Attending Tertiary Care Hospital},
  journal = {International Journal of Current Pharmaceutical Review and Research},
  year = {2026},
  volume = {18},
  number = {04},
  doi = {10.25258/ijcpr.18.4.201}
}
Kostenlos starten →